Orphan Drug Status Granted for SNS01-T for Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma

Senesco Technologies reported that the FDA has granted orphan-drug designation for the company’s lead drug candidate SNS01-T for treatment of both mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL).

SNS01-T is a novel approach to cancer therapy that is designed to selectively trigger apoptosis in B-cell cancers. Senesco was previously granted orphan drug status for SNS01-T for treatment of multiple myeloma.

For more information visit www.senesco.com.